Fibroblast proliferation and differentiation

Fibroblast proliferation and differentiation is a fundamental biological process involved in tissue repair and wound healing, but it is not a single molecular target. This process describes the activation of quiescent fibroblasts into proliferative, contractile myofibroblasts, primarily driven by cytokines such as transforming growth factor-beta (TGF-β) and various growth factors (Wynn, 2007, J. Clin. Invest.). In pathological states, such as idiopathic pulmonary fibrosis (IPF) or systemic sclerosis, this process becomes chronic and leads to excessive deposition of extracellular matrix (ECM) and organ dysfunction (Richeldi et al., 2014, NEJM). Pharmacological intervention typically targets the signaling receptors that initiate this process, such as the platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). For instance, the multi-kinase inhibitor nintedanib is approved for treating fibrotic lung diseases by blocking these pathways to reduce fibroblast activity (King et al., 2014, NEJM). Monitoring this process often involves measuring biomarkers like alpha-smooth muscle actin (α-SMA) or collagen synthesis markers (Hinz, 2007, J. Invest. Dermatol.). Therapeutic challenges include the risk of impaired normal wound healing and systemic toxicities due to the broad role of fibroblasts in maintaining tissue integrity.

Other names

Fibroblast activationMyofibroblast differentiationFibroproliferationFibroblast-to-myofibroblast transition

Inhibition of tyrosine kinase receptors (PDGFR, FGFR, VEGFR) or neutralization of profibrotic cytokines (TGF-beta, CTGF) to prevent fibroblast activation and extracellular matrix deposition.